CN116490178A - Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 - Google Patents
Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 Download PDFInfo
- Publication number
- CN116490178A CN116490178A CN202080105705.3A CN202080105705A CN116490178A CN 116490178 A CN116490178 A CN 116490178A CN 202080105705 A CN202080105705 A CN 202080105705A CN 116490178 A CN116490178 A CN 116490178A
- Authority
- CN
- China
- Prior art keywords
- composition
- sglt
- inhibitor
- medicament
- angiotensin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title claims abstract description 26
- 229940125364 angiotensin receptor blocker Drugs 0.000 title abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 36
- 206010020772 Hypertension Diseases 0.000 claims abstract description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 23
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims description 51
- 239000000463 material Substances 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 17
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 15
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims description 15
- 229960003834 dapagliflozin Drugs 0.000 claims description 15
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 229960002198 irbesartan Drugs 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000005480 Olmesartan Substances 0.000 claims description 7
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 7
- 229960005117 olmesartan Drugs 0.000 claims description 7
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 6
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 6
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 6
- 229960001713 canagliflozin Drugs 0.000 claims description 6
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 6
- 229960000932 candesartan Drugs 0.000 claims description 6
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 6
- 229960004773 losartan Drugs 0.000 claims description 6
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 6
- 229960004699 valsartan Drugs 0.000 claims description 6
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 208000007530 Essential hypertension Diseases 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 claims description 4
- 239000005485 Azilsartan Substances 0.000 claims description 4
- 208000002249 Diabetes Complications Diseases 0.000 claims description 4
- 206010012655 Diabetic complications Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims description 4
- 229960002731 azilsartan Drugs 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229960003345 empagliflozin Drugs 0.000 claims description 4
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- -1 glidant Substances 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229950005268 sotagliflozin Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 3
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 claims description 3
- 230000036765 blood level Effects 0.000 claims description 3
- 229960004563 eprosartan Drugs 0.000 claims description 3
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 229940126844 remogliflozin Drugs 0.000 claims description 3
- 229950011516 remogliflozin etabonate Drugs 0.000 claims description 3
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 claims description 3
- 229960005187 telmisartan Drugs 0.000 claims description 3
- HYTPDMFFHVZBOR-VNXMGFANSA-N (1r,2s,3s,4r,5r)-5-[4-chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound C1=C(F)C(OCC)=CC=C1CC1=CC([C@]23O[C@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl HYTPDMFFHVZBOR-VNXMGFANSA-N 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 239000006068 taste-masking agent Substances 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 3
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 11
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 10
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 abstract description 8
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 abstract description 8
- 208000001647 Renal Insufficiency Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 201000006370 kidney failure Diseases 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 230000001934 delay Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 25
- 239000002994 raw material Substances 0.000 description 25
- 239000004480 active ingredient Substances 0.000 description 24
- 238000005303 weighing Methods 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 238000007873 sieving Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000007779 soft material Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 229960003943 hypromellose Drugs 0.000 description 6
- 239000011812 mixed powder Substances 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229940000201 avapro Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 229920006310 Asahi-Kasei Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
涉及药物领域,特别涉及SGLT‑2抑制剂与血管紧张素受体阻滞剂的组合物及用途,具体涉及一种固定剂量的钠‑葡萄糖协同转运蛋白2(SGLT‑2)抑制剂与血管紧张素受体阻滞剂(ARBs)的复方组合物及用途。该固定剂量复方组合物用于糖尿病伴高血压患者的治疗,同时使慢性肾病患者获益,预防或延缓慢性肾脏病(CKD)患者肾功能衰竭恶化、预防心血管(CV)死亡或肾病死亡。另外,所涉及的固定剂量复方组合物具有良好的协同性、稳定性好、携带或服用方便,用药成本显著降低,同时避免了多服、漏服的风险,改善了患者服药的顺应性。
Description
本发明涉及药物领域,特别涉及SGLT-2抑制剂与血管紧张素受体阻滞剂的组合物及用途。
高血压是心血管疾病的主要危险因素,尤其是对于合并糖尿病的患者,两者相加对心血管的危害有协同效应。而2型糖尿病患者异常升高的血糖及胰岛素抵抗是包括高血压病在内的多种心血管疾病发病的独立危险因素,与此同时,控制2型糖尿病患者的血压以及避免血压过度波动,在预防或控制糖尿病患者的远期心血管并发症方面具有显著的功效,当这些危险因素得到有效控制时,获益非常明显。据相关流行病学调查研究显示,近年来,中国的高血压与糖尿病的患病率均呈逐年上升趋势,在心内科就诊的高血压患者有32.9%同时合并糖尿病,而在内分泌科就诊的糖尿病患者中则有58.9%合并高血压。在总体人群中,有45.3%的患者二病共患。糖尿病病人中高血压的患病率明显增高,约为非糖尿病人群的2倍。在美国,糖尿病是美国成人中患病率最高的,并且大约一半的糖尿病患者均同时患有高血压,这无疑加大了糖尿病人的心血管负担。糖尿病合并高血压进一步增加了2型糖尿病患者的左心室壁肥厚、蛋白尿和肾功能损伤等风险,增加了心血管疾病患者的不良心血管事件的发生,增加了这类患者的经济负担。高血压病合并2型糖尿病严重损害患者的心、脑、肾等身体重要靶器官和机体血管***,进而出现冠状动脉粥样硬化性心脏病、心功能不全、神经中枢血管缺血或出血性卒中以及肾功能不全甚至***等并发症,严重影响到这类患者的机体健康及生存质量。因此,高血压和糖尿病合并发生时,同时控制血糖和血压,才能更加有效地减少并发症的发生,降低死亡风险。
高血压以及糖尿病发病率以及死亡率均较高,确诊后需及时进行相关治疗,但对于糖尿病伴高血压病患而言,由于其同时患有两种疾病,为临 床治疗带来一定挑战。临床治疗糖尿病伴高血压方法较多,其中药物治疗最为常见。但糖尿病伴高血压病患大多为老年人,且均为终生服药,针对该类病患治疗一方面需尽可能提升治疗效果,另一方面尽量减少不良反应的出现,增加病患治疗依从性,从而获得满意的治疗效果。厄贝沙坦(活性成分A)为血管紧张素受体阻滞剂,具有较高的选择性,在竞争拮抗的同时不会产生激动作用,通过抑制肾上腺素释放醛固酮以及扩张血管来达到降血压的目的。厄贝沙坦通过抑制系膜内细胞数量的增殖,减少体内基底蛋白含量,提升机体尿白蛋白***率,达到保护肾脏的目的。厄贝沙坦用于治疗原发性高血压以及合并高血压的2型糖尿病肾病的治疗。临床研究证明,厄贝沙坦使高血压伴2型糖尿病患者的肾脏受益。
达格列净(活性成分B)是一种钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂,具有极高的选择性和特异性,该药物进入体内后通过阻断曲小管对机体内葡萄糖的吸收,增加机体***量,降低糖化血红蛋白水平,达到控制血糖的目的,更让人兴奋的是SGLT-2抑制剂在降低血压方面也显示出了良好的前景,这为糖尿病及高血压的治疗提供了新的、独特的思路。近期SGLT-2抑制剂临床试验显示,糖尿病患者的收缩压降低4mmHg时,其舒张压仅降低1.6mmHg,而通常的降压药单药治疗当收缩压降低9.1mmHg时,舒张压要降低5.5mmHg,舒张压降得过低,会导致心脏缺血风险。2019年,达格列净被美国食品和药物管理局(FDA)授予快速通道资格,以延缓慢性肾脏病(CKD)患者肾功能衰竭恶化以及预防心血管(CV)和肾脏死亡,包括患有或不患有2型糖尿病(T2D)的CKD患者。
对于糖尿病伴高血压的患者,SGLT-2抑制剂和血管紧张素受体拮抗 剂同服可达到同时降低血压和血糖的效果,且可使肾脏和心血管受益,预防或延缓慢性肾脏病(CKD)患者肾功能衰竭恶化以及预防心血管(CV)和肾脏死亡。目前临床上将两者的单方制剂同时给患者服用,存在携带或服用不便,顺应性差,某一药物存在多服或漏服的风险、潜在的安全隐患及用药成本较高,目前还没有厄贝沙坦和达格列净的复方制剂上市,也没有相关复方制剂专利。
发明内容
有鉴于此,本发明提供了SGLT-2抑制剂与血管紧张素受体阻滞剂的组合物及用途。该组合物用于糖尿病伴高血压治疗,同时使患者肾脏或心血管受益,降低2型糖尿病患者心血管和肾脏并发症的发生风险。本发明组合物携带或服用方便,用药成本相对降低,避免了多服漏服的风险,改善了患者服药的顺应性。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了组合物,包括SGLT2抑制剂和血管紧张素-II受体拮抗剂。
在本发明的一些具体实施方案中,所述SGLT-2抑制剂包括但不限于达格列净(Dapagliflozin)、坎格列净(Canagliflozin)、恩格列净(Empagliflozin)、依格列净(Ipragliflozin)、鲁格列净(Luseogliflozin)、托格列净(Tofogliflozin)、埃格列净(Ertugliflozin)、加格列净(Janagliflozin)、贝格列净(Bexagliflozin)、索格列净(Sotagliflozin)、恒格列净(Henagliflozin)、泰格列净(Tianagliflozin)、瑞格列净(Remogliflozin)、艾格列净(Alligliflozin)、依碳酸瑞格列净(Remogliflozin etabonate)、荣格列净((1R,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-((R)-1-hydroxy ethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol)中的一种或两者以上的组合。
在本发明的一些具体实施方案中,所述血管紧张素-II受体拮抗剂包括但不限于厄贝沙坦(Irbesartan)、坎地沙坦(Candesartan)、缬沙坦 (Valsartan)、替米沙坦(Telmisartan)、洛沙坦(Losartan)、依普沙坦(Iprasartan)、奥美沙坦(Olmesartan)、阿齐沙坦(Azilsartan)中的一种或两者以上的组合。
在本发明的一些具体实施方案中,所述SGLT-2抑制剂包括达格列净或其药用盐、酯、共晶、络合物或溶剂合物中的一种或两者以上的组合;所述血管紧张素-II受体拮抗剂包括厄贝沙坦、其可药用盐或溶剂合物中的一种或两者以上的组合。
在本发明的一些具体实施方案中,所述SGLT-2抑制剂和所述血管紧张素-II受体拮抗剂的重量比为1:960~300:1,优选1:240~75:1,更优选1:120~1:7.5,更优选(8~300):(2~300),最优选8:300、20:12.3、40:12.3、50:4.1、50:2、44.8:3.7、32.5:2.7、150:12.3、150:6.15、75:12.3、300:6.15或300:12.3。
在上述研究的基础上,所述的组合物在制备治疗原发性高血压、合并高血压的2型糖尿病肾病、糖尿病、胰岛素抵抗、高血糖、高胰岛素血症、脂肪酸或甘油的升高的血含量、高脂血、血脂障碍、肥胖、或糖尿病并发症的药物中的应用。
本发明还提供了药物,包括所述的组合物及药学上可接受的辅料。
在本发明的一些具体实施方案中,所述辅料包括但不限于:填充剂,粘合剂,崩解剂,抗粘剂,吸附剂,助流剂,润滑剂,表面活性剂,螯合剂,着色剂,掩味剂中的一种或两者以上的组合。
在本发明的一些具体实施方案中,所述药物的剂型包括片剂、胶囊剂、颗粒剂、混悬剂、膜剂中的一种多种,优选为片剂、干混悬剂、胶囊剂、颗粒剂。
在本发明的一些实施方案中,所述药物为片剂、颗粒剂或胶囊剂,其包含:
a)SGLT-2抑制剂和血管紧张素-II受体阻滞剂;
b)任选的一种或多种填充剂;
c)任选的一种或多种粘合剂;
d)任选的一种或多种崩解剂;
e)任选的一种或多种抗粘剂或吸附剂;
f)任选的一种或多种助流剂或润滑剂;
g)任选的一种或多种表面活性剂;
h)任选的一种或多种着色剂;
i)任选的一种或多种矫味剂。
其中SGLT-2抑制剂包括但不限于达格列净(Dapagliflozin)、坎格列净(Canagliflozin)、恩格列净(Empagliflozin)、依格列净(Ipragliflozin)、鲁格列净(Luseogliflozin)、托格列净(Tofogliflozin)、埃格列净(Ertugliflozin)、加格列净(Janagliflozin)、贝格列净(Bexagliflozin)、索格列净(Sotagliflozin)、恒格列净(Henagliflozin)、泰格列净(Tianagliflozin)、瑞格列净(Remogliflozin)、艾格列净(Alligliflozin)、依碳酸瑞格列净(Remogliflozin etabonate)、荣格列净((1R,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-((R)-1-hydroxy ethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol)中的一种或多种。优选自达格列净。优选自达格列净或其药用盐、酯、共晶、络合物或溶剂合物。
血管紧张素-II受体拮抗剂包括但不限于厄贝沙坦(Irbesartan)、坎地沙坦(Candesartan)、缬沙坦(Valsartan)、替米沙坦(Telmisartan)、洛沙坦(Losartan)、依普沙坦(Iprasartan)、奥美沙坦(Olmesartan)、阿齐沙坦(Azilsartan)。优选自厄贝沙坦、其可药用盐、共晶、络合物或溶剂合物。
本发明组合物中的稀释剂可以是一种或多种能提供获得期望的片剂体积的化合物。理想的稀释剂包含但不限于微晶纤维素、乳糖、甘露醇、赤藓醇、麦芽糖醇、山梨糖醇、海藻糖、蔗糖、白糖、葡萄糖、果糖、玉米淀粉、小麦淀粉、糊精、甘草粉末、磷酸钙、磷酸氢钙、碳酸钙、柠檬酸钙、乳酸钙、氧化镁、氢氧化镁、氧化钙、碳酸镁、碳酸钾、碳酸锌、氧化钛、硅酸酐、硅酸镁、硅酸钙、碳酸氢钠、硫酸镁、硫酸钙、二氧化硅。
本发明组合物中的粘合剂可以是使得主药和辅料能成为期望的自由流动的颗粒的一种或多种化合物。理想的粘合剂包括但不限于羟丙基纤维素、羟丙甲纤维素、白糖、明胶、淀粉、***胶、黄芪胶、羧甲基纤维 素、聚乙烯吡咯烷酮、甲基纤维素、部分α化淀粉、α化淀粉、聚乙烯醇、海藻酸钠、普鲁兰多糖、甘油。
本发明组合物中的崩解剂可以是能促进组合物与水介质接触时崩解的一种或多种化合物。优选的崩解剂包括但不限于玉米淀粉、部分α化淀粉、羟丙基淀粉、羧甲基纤维素、羧甲基纤维素钠、羧甲基纤维素钙、羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、交聚维酮。
本发明组合物中的抗粘剂或吸附剂指的是能降低制剂的粘度或吸附制剂中的液体成分,防止其黏着于金属表面的一种或多种化合物。抗粘剂或吸附剂包括但不限于二氧化硅、硅酸镁、滑石、磷酸氢钙等。
本发明组合物中的助流剂可以是能降低颗粒之间的摩擦力,改善粉体流动性,有助于减少重量差异的一种或多种化合物,助流剂包括但不限于滑石粉、二氧化硅。
本发明组合物中的润滑剂是可以降低物料与模壁之间的摩擦力,保证压片推片、胶囊灌装或颗粒分装顺利进行的一种或多种化合物。润滑剂包括但不限于硬脂酸镁、硬脂酸、硬脂酸钙、硬脂富马酸钠、聚乙二醇、氢化植物油、聚乙二醇、十二烷基硫酸钠。
本发明组合物中的表面活性剂指的是可改善制剂润湿性和/或促进溶解的一种或多种化合物。表面活性剂包括但不限于泊洛沙姆、十二烷基硫酸钠、吐温、司盘。
本发明组合物中的着色剂指能给予组合物制备的制剂期望的颜色的一种或多种化合物。着色剂包括但不限于苋菜红、胭脂红、赤藓红、新红、柠檬黄、日落黄、喹啉黄、靛蓝、亮蓝、甜菜红、紫胶红、越桔红、辣椒红、红米红等。
本发明组合物中的矫味剂指用以改善或屏蔽药物不良气味和味道的一种或多种化合物。矫味剂包括但不限于蔗糖、甘露醇、山梨醇、枸橼酸钠、阿斯巴甜、薄荷油、香精、海藻酸钠、***胶。
在本发明的一些具体实施方案中,所述SGLT-2抑制剂和所述血管紧张素-II受体拮抗剂的混合方式包括:
(1)直接混合;或
(2)分别作为内加组分或外加组分;或
(3)同时作为内加组分。
在本发明的一些具体实施方案中,所述血管紧张素-II受体拮抗剂作为内加组分,所述SGLT-2抑制剂作为外加组分。
本发明还提供了所述的药物的制备方法,将原辅料直接混合。
本发明还提供了所述的药物的制备方法,包括混合、制粒、整粒、总混的步骤。
本发明还提供了所述的药物的制备方法,包括混合、制粒、干燥、整粒、总混的步骤。
此外,本发明提供的药物制备方法中,所述SGLT-2抑制剂和所述血管紧张素-II受体拮抗剂的混合方式包括:
(1)直接混合;或
(2)分别作为内加组分或外加组分;或
(3)同时作为内加组分。
在本发明的一些具体实施方案中,本发明提供的药物制备方法中所述血管紧张素-II受体拮抗剂作为内加组分,所述SGLT-2抑制剂作为外加组分。
本发明还提供了所述的药物或所述制备方法制得的药物在制备治疗原发性高血压、合并高血压的2型糖尿病肾病、糖尿病、胰岛素抵抗、高血糖、高胰岛素血症、脂肪酸或甘油的升高的血含量、高脂血、血脂障碍、肥胖、或糖尿病并发症的药物中的应用。
本发明提供一种固定剂量的SGLT-2抑制剂和血管紧张素-II受体拮抗剂的组合物。该组合物用于糖尿病伴高血压治疗,同时可使肾脏受益,预防或延缓慢性肾脏病(CKD)患者肾功能衰竭恶化以及预防心血管(CV)和肾脏死亡。另外,本发明所涉及的固定剂量复方组合物具有良好的协同性、稳定性好、携带或服用方便,用药成本显著降低,同时避免了多服、漏服的风险,改善了患者服药的顺应性。
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示活性成分A在pH1.0盐酸溶液中的累积溶出度(%);
图2示活性成分B在pH1.0盐酸溶液中的累积溶出度(%)。
本发明公开了一种固定剂量的钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂与血管紧张素受体阻滞剂(ARBs)的复方组合物及用途,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明提供的固定剂量的钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂与血管紧张素受体阻滞剂(ARBs)的复方组合物及用途中所用原辅料均可由市场购得。
乳糖(FOREMOST)、甘露醇(ROQUETTE)、蔗糖(四川博利恒)、碳酸钙(上海诺诚)、氧化镁(河北伯斯特)、交聚维酮(BASF)、交联羧甲基纤维素钠(旭化成)、羟丙甲纤维素(陶氏化学)、微晶纤维素(JRS)、二氧化硅(湖州展望)、硬脂酸镁(湖州展望)、低取代羟丙纤维素(信越化学)、羟丙纤维素(曹达化学)、预胶化淀粉(ASAHI KASEI)、滑石粉(广西龙胜华美)、硬脂富马酸钠(上海昌为)、明胶空心胶囊(苏州胶囊有限公司)、羟丙甲纤维素空心胶囊(苏州胶囊有限公司)。
下面结合实施例,进一步阐述本发明:
实施例1~实施例15
表1以重量百分比计的处方组成(%)
表2以重量百分比计的处方组成(%)
制备工艺:
称取处方量的原辅料混匀。将各实施例混粉分别用干净的称量纸包好后放入铝箔袋中封好,于50℃放置10天取样测定有关物质,与对比例比较。因活性成分B较稳定,影响因素放置后无增长杂质所以本发明只列出活性成分A的有关物质。
表3以重量百分比计的处方组成(%)
制备工艺:
实施例13:称取100粒处方量的内加原辅料袋混15分钟;然后加入纯化水制软材,40目筛制粒,或50℃干燥,40目筛整粒,水分控制在2%或以下;折算称取外加原辅料袋混10分钟,装入明胶胶囊。
实施例14:按50片处方量称取内加原辅料混合均匀,使用纯化水制软材,80目筛制粒,40℃干燥,80目筛整粒,水分控制在2%或以下,折算称取外加原辅料过80目筛混8次,然后加入对应的干颗粒混匀,压片。
实施例15:称取50粒处方量的内加原辅料混匀;然后用纯化水制软材,40目筛制粒,50℃干燥,40目筛整粒;称取外加原辅料混匀,干法30目筛制粒;将内外加原辅料颗粒按比例混匀,装羟丙甲纤维素胶囊。
表4活性成分A有关物质测定结果(%)
注1:Avapro为活性成分A单方片剂参比制剂的商品,批号:DT04448。
结论:由活性成分A的有关物质结果知,对比例在RRT 0.85处有一杂质高温放置后增长,而实施例1~实施例15高温放置后无明显增长的杂质,总杂也较小。
实施例16~实施例18
表5单位制剂处方组成(mg/片)
制备工艺:
按50片处方量称取活性成分B、无水乳糖、交联羧甲基纤维素钠、泊洛沙姆188和二氧化硅过65目筛混合6次,再加入活性成分A和预胶化淀粉过65目筛混合8次;干法制粒;折算加入外加辅料混匀,压片。考察pH1.0盐酸介质中的15分钟的溶出度。溶出方法:pH1.0盐酸溶液,桨法,介质体积:900ml,温度:37℃,转速:50rpm。判定方法:活性成分A与活性成分B的单方参比制剂的15分钟溶出均在85%以上,实施例的溶出要求与参比制剂一致,所以目标值也为85%以上。
实施例19~实施例20
表6单位制剂处方组成(mg/片)
制备工艺:
称取50片处方量的内加原辅料过筛混匀;实施例19使用10%的羟丙甲纤维素水溶液制软材,65目筛制粒,40℃干燥,65目筛整粒,折算加入外加辅料混匀;实施例20干法制粒,折算加入外加辅料混匀。测定pH1.0盐酸介质中15分钟的溶出。测定方法:桨法,介质体积:1000ml,温度:37℃,转速:50rpm。如无特殊说明,之后实施例的溶出均以此方法测定。
实施例21~实施例24
表7单位制剂处方组成(mg/片)
制备工艺:
按50片处方量称取内加原辅料混合均匀,向实施例21中加入纯化水制软材,40目筛制粒,50℃干燥,40目筛整粒,折算加入外加辅料袋混10分钟,压片。向实施例22的混粉中加入羟丙甲纤维素水溶液制软材,实施例23和实施例24使用纯化水制软材,80目筛制粒,40℃干燥,80目筛整粒,水分控制在2%或以下,折算称取外加原辅料过80目筛混8次,然后加入对应的干颗粒混匀,压片。测定pH1.0盐酸介质中15分钟的溶出度。
表8实施例16~实施例24的溶出度结果
溶出度(%) | 活性成分A | 活性成分B |
实施例16 | 94.2 | 93.5 |
实施例17 | 93.7 | 87.0 |
实施例18 | 93.8 | 94.7 |
实施例19 | 95.5 | 92.8 |
实施例20 | 95.6 | 93.0 |
实施例21 | 99.0 | 94.6 |
实施例22 | 89.8 | 86.2 |
实施例23 | 97.7 | 90.0 |
实施例24 | 91.0 | 88.8 |
对比例/Avapro(8A430) | 92.6 | / |
对比例/FORXIGA(KJ3245) | / | 97.4 |
结论:各实施例的活性成分A和活性成分B的15分钟的溶出均大于85%,与对应的对比例的溶出一致。
实施例25~实施例30
表9单位制剂处方组成(mg/片)
制备工艺:
称取处方量的活性成分A、交联聚维酮、一水乳糖和羟丙甲纤维素混匀;加入纯化水制软材,80目筛制粒,40℃干燥,80目筛整粒,水分控制在2%或以下;折算称取外加原辅料过80目筛混合8次,然后加入干颗粒混匀;压片。测定pH1.0盐酸介质中15分钟的溶出度。
表10实施例25~实施例30的溶出度结果
溶出度(%) | 活性成分A | 活性成分B |
实施例25 | 99.0 | 95.8 |
实施例26 | 98.5 | 88.9 |
实施例27 | 98.6 | 96.4 |
实施例28 | 93.5 | 95.2 |
实施例29 | 100.6 | 88.0 |
实施例30 | 95.8 | 92.1 |
对比例/Avapro(ET01506,规格:75mg) | 90.0 | / |
对比例/Avapro(DT04448,规格:150mg) | 92.6 | / |
对比例/Avapro(DT03090A,规格:300mg) | 93.2 | / |
对比例/FORXIGA(LB0143,规格:5mg) | / | 92.1 |
对比例/FORXIGA(KJ3245,规格:10mg) | / | 91.8 |
实施例31~实施例33
表11单位制剂处方组成(mg/片)
制备工艺:
实施例31:称取100片处方量的内加原辅料混匀;混粉用纯化水制软材,40目筛制粒,50℃干燥,40目筛整粒;折算称取外加原辅料混匀;压片。
实施例32:称取25片处方量的内加原辅料混匀,然后用纯化水制软材,40目筛制粒,60℃干燥,40目筛整粒;所得干颗粒折算加入外加原辅料混匀;压片。
实施例33:称取25片处方量的内加原辅料混匀;然后加入纯化水制软材,40目筛制粒,40℃干燥,40目筛整粒;折算称取外加原辅料混匀,压片。
测定各实施例在pH1.0盐酸介质中15分钟的溶出度,结果如下:
表12实施例31~实施例33的溶出度结果
溶出度(%) | 活性成分A | 活性成分B |
实施例31 | 97.1 | 94.8 |
实施例32 | 89.7 | 86.5 |
实施例33 | 86.7 | 87.9 |
实施例34~实施例40
表13单位制剂处方组成(mg/片)
表14单位制剂处方组成(mg/片)
制备工艺:
实施例34、37:a)称取100片处方量的第一层除氢氧化钠和硬脂酸镁外的原辅料混匀;混粉用氢氧化钠水溶液制软材,40目筛制粒,40℃干燥,40目筛整粒;折算加入硬脂酸镁混匀;b)称取第二层的原辅料混匀;c)将第一层总混颗粒和第二层的混粉压双层片。
实施例35、36:a)称取100片处方量的第一层原辅料混匀;b)称取第二层的原辅料混匀;c)将第一层的混粉和第二层的混粉压双层片。
实施例38~实施例40:a)称取100片处方量的第一层的部分硬脂酸镁和全部其他原辅料混匀,干法制粒,然后加入剩余硬脂酸镁混匀;b)称取第二层的部分二氧化硅、硬脂酸镁和所有其他原辅料混匀,干法制粒, 然后加入剩余二氧化硅和硬脂酸镁混匀;c)将第一层的总混颗粒和第二层的总混颗粒压双层片。
测定部分实施例在pH1.0盐酸介质中15分钟的溶出度,结果如下:
表15实施例39、实施例40的溶出度结果
溶出度(%) | 奥美沙坦 | 活性成分A | 活性成分B |
实施例39 | 85.6 | / | 89.8 |
实施例40 | / | 87.3 | 90.1 |
效果例
表16单位制剂处方组成(mg/片)
制备工艺:
称取100片处方量的内加原辅料袋混15分钟;然后加入纯化水制软材,40目筛制粒,40℃(实施例42)或50℃(实施例41)干燥,40目筛整粒,水分控制在2%或以下;折算称取外加原辅料袋混10分钟,压片。测定实施例在pH1.0盐酸介质中的溶出曲线。
表17活性成分A在pH1.0盐酸溶液中的累计溶出度(%)
表18活性成分B在pH1.0盐酸溶液中的累计溶出度(%)
表19活性成分A有关物质测定结果(%)
将实施例41和42的自制制剂和参比制剂进行比格犬的PK研究。使用3只比格犬(11.6–14.8kg)进行3周期3交叉研究,其中单方参比制剂A和参比制剂B同时给药。给药后分别于0.25、0.5、0.75、1、1.5、2、2.5、3、4、6、8、12和24h取血,使用LC-MS进行检测。结果如下:
表20活性成分A的动物实验结果
表21活性成分B的动物实验结果
结论:由上述结果知,自制制剂与原研制剂在比格犬体内C
max Ratio和AUC
0-24Ratio均在80%-125%范围内,说明自制制剂与原研制剂在比格犬体内生物等效。
以上对本发明所提供的SGLT-2抑制剂与血管紧张素受体阻滞剂的组合物及用途进行了详细介绍。本文应用了具体个例对本发明的原理及实施方式进行了阐述,以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。应当指出,对于本技术领域技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也落入本发明权利要求的保护范围内。
Claims (15)
- 组合物,其特征在于,包括SGLT-2抑制剂和血管紧张素-II受体拮抗剂。
- 如权利要求1所述的组合物,其特征在于,所述SGLT-2抑制剂包括但不限于达格列净(Dapagliflozin)、坎格列净(Canagliflozin)、恩格列净(Empagliflozin)、依格列净(Ipragliflozin)、鲁格列净(Luseogliflozin)、托格列净(Tofogliflozin)、埃格列净(Ertugliflozin)、加格列净(Janagliflozin)、贝格列净(Bexagliflozin)、索格列净(Sotagliflozin)、恒格列净(Henagliflozin)、泰格列净(Tianagliflozin)、瑞格列净(Remogliflozin)、艾格列净(Alligliflozin)、依碳酸瑞格列净(Remogliflozin etabonate)、荣格列净((1R,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-((R)-1-hydroxy ethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol)中的一种或两者以上的组合。
- 如权利要求1或2所述的组合物,其特征在于,所述血管紧张素-II受体拮抗剂包括但不限于厄贝沙坦(Irbesartan)、坎地沙坦(Candesartan)、缬沙坦(Valsartan)、替米沙坦(Telmisartan)、洛沙坦(Losartan)、依普沙坦(Iprasartan)、奥美沙坦(Olmesartan)、阿齐沙坦(Azilsartan)中的一种或两者以上的组合。
- 如权利要求1至3任一项所述的组合物,其特征在于,所述SGLT-2抑制剂包括达格列净或其药用盐、酯、共晶、络合物或溶剂合物中的一种或两者以上的组合;所述血管紧张素-II受体拮抗剂包括厄贝沙坦、其可药用盐或溶剂合物中的一种或两者以上的组合。
- 如权利要求1至4任一项所述的组合物,其特征在于,所述SGLT-2抑制剂和所述血管紧张素-II受体拮抗剂的重量比为1:960~300:1,优选1:240~75:1,更优选1:120~1:7.5,更优选(8~300):(2~300),最优选8:300、20:12.3、40:12.3、50:4.1、50:2、44.8:3.7、32.5:2.7、150:12.3、150:6.15、75:12.3、300:6.15或300:12.3。。
- 如权利要求1至5任一项所述的组合物在制备治疗原发性高血压、合并高血压的2型糖尿病肾病、糖尿病、胰岛素抵抗、高血糖、高胰岛素血症、脂肪酸或甘油的升高的血含量、高脂血、血脂障碍、肥胖、或糖尿病并发症的药物中的应用。
- 药物,其特征在于,包括如权利要求1至5任一项所述的组合物及药学上可接受的辅料。
- 如权利要求7所述的药物,其特征在于,所述辅料包括但不限于:填充剂,粘合剂,崩解剂,抗粘剂,吸附剂,助流剂,润滑剂,表面活性剂,螯合剂,着色剂,掩味剂中的一种或两者以上的组合。
- 如权利要求7或8所述的药物,其特征在于,其剂型包括片剂、胶囊剂、颗粒剂、混悬剂、膜剂中的一种多种,优选为片剂、干混悬剂、胶囊剂、颗粒剂。
- 如权利要求7至9任一项所述的药物,其特征在于,所述SGLT2抑制剂和所述血管紧张素-II受体拮抗剂的混合方式包括:(1)直接混合;或(2)分别作为内加组分或外加组分;或(3)同时作为内加组分;或(4)分别压片再压制成双层片。
- 如权利要求10所述的药物,其特征在于,所述血管紧张素-II受体拮抗剂作为内加组分,所述SGLT-2抑制剂作为外加组分。
- 如权利要求7至11任一项所述的药物的制备方法,其特征在于,将原辅料直接混合。
- 如权利要求7至11任一项所述的药物的制备方法,其特征在于,包括混合、制粒、整粒、总混的步骤。
- 如权利要求7至1任一项所述的药物的制备方法,其特征在于,包括混合、制粒、干燥、整粒、总混的步骤。
- 如权利要求7至11任一项所述的药物或如权利要求12~14任一项所述制备方法制得的药物在制备治疗原发性高血压、合并高血压的2型糖尿病肾病、糖尿病、胰岛素抵抗、高血糖、高胰岛素血症、脂肪酸或 甘油的升高的血含量、高脂血、血脂障碍、肥胖、或糖尿病并发症的药物中的应用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/109533 WO2022036506A1 (zh) | 2020-08-17 | 2020-08-17 | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116490178A true CN116490178A (zh) | 2023-07-25 |
Family
ID=80323266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080105705.3A Pending CN116490178A (zh) | 2020-08-17 | 2020-08-17 | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230346817A1 (zh) |
EP (1) | EP4197543A4 (zh) |
KR (1) | KR20230057388A (zh) |
CN (1) | CN116490178A (zh) |
WO (1) | WO2022036506A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106316975A (zh) * | 2015-06-15 | 2017-01-11 | 山东轩竹医药科技有限公司 | 酰胺类化合物及其作为tgr5激动剂的应用 |
KR101943382B1 (ko) * | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
WO2020039394A1 (en) * | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
-
2020
- 2020-08-17 EP EP20949719.7A patent/EP4197543A4/en active Pending
- 2020-08-17 KR KR1020237009242A patent/KR20230057388A/ko unknown
- 2020-08-17 WO PCT/CN2020/109533 patent/WO2022036506A1/zh active Application Filing
- 2020-08-17 CN CN202080105705.3A patent/CN116490178A/zh active Pending
- 2020-08-17 US US18/025,751 patent/US20230346817A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4197543A4 (en) | 2024-05-15 |
WO2022036506A1 (zh) | 2022-02-24 |
EP4197543A1 (en) | 2023-06-21 |
US20230346817A1 (en) | 2023-11-02 |
KR20230057388A (ko) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110548026B (zh) | 含有葡萄糖激酶激活剂和k-atp通道阻断剂的药物组合及其制备方法和用途 | |
TWI564034B (zh) | 含1-(β-D-葡萄吡喃糖苷)-3-(苯基噻吩基甲基)苯化合物之錠劑 | |
JP6976946B2 (ja) | 生理活性の強い、urat1のインヒビターを含む医薬組成物 | |
KR20140007247A (ko) | 음식물 영향이 감소된 제어 방출 조성물 | |
KR101977785B1 (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 | |
TWI606848B (zh) | 包含格米列汀與美氟明的組合藥物及其製備方法 | |
KR20120104523A (ko) | 디펩티딜 펩티다제―4 억제제와 피오글리타존의 조합물의 제약 조성물 | |
EP4051246A1 (en) | Bilayer tablet formulations comprising dapagliflozin and metformin | |
US20150283248A1 (en) | Pharmaceutical compositions of Linagliptin and process for preparation thereof | |
EP4112047A1 (en) | Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin | |
WO2021176096A1 (en) | Pharmaceutical composition comprising sglt2 inhibitor | |
JP2023514005A (ja) | シタグリプチン及びダパグリフロジンを含む複合製剤及びその製造方法 | |
CN111202731B (zh) | 联合用药应用以及一种药用组合物及其应用 | |
WO2022036506A1 (zh) | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 | |
KR102409102B1 (ko) | 제약 조성물 | |
WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
EP4162929A1 (en) | Composite formulation comprising sitagliptin and dapagliflozin and preparation method therefor | |
US11096945B2 (en) | Pharmaceutical compositions of linagliptin and process for preparation thereof | |
WO2022263935A1 (en) | Pharmacutical composition comprising remogliflozin etabonate, metformin hydrochloride and vildagliptin | |
WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
EP4212150A1 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
WO2022119542A1 (en) | Solid pharmaceutical formulations of amorphous dapagliflozin | |
CN117677378A (zh) | 包含西他列汀、达格列净和二甲双胍的经口复合片剂 | |
WO2023136797A2 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
WO2022119540A2 (en) | A process for formulations of dapagliflozin and metformin hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |